Final Overall Survival (OS) Results from a Phase III, Randomized, Open-label, First-line Study of Gefitinib (G) V Carboplatin/Paclitaxel (C/P) in Clinically Selected Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) in Asia (IPASS)
Refereed conference paper presented and published in conference proceedings

香港中文大學研究人員

全文

其它資訊
著者MOK Shu Kam Tony, YANG H C, FUKUOKA M, WU L Y, THONGPRASERT S, SAIJO N, CHU T D, JIANG H, DUFFIELD L E, ICHINOSE Y
會議名稱35th ESMO Congress
會議國家/地區英國
會議論文集題名35th ESMO Congress
詳細描述organized by European Society for Medical Oncology,
出版年份2010
月份10
出版地United Kingdom
頁次2
語言英式英語
關鍵詞Gefitinib; NSCLC

上次更新時間 2018-23-01 於 20:26